DDInter1294 DDInter1024
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Lapatinib
Nilutamide {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Nilutamide {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Nilutamide {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Nilutamide {u} (Compound) causes {v} (Side Effect) Interstitial lung disease
Interstitial lung disease {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Nilutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Lapatinib (Compound)
Nilutamide (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Nilutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Nilutamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Nilutamide (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Nilutamide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Nilutamide (Compound) causes Interstitial lung disease (Side Effect) and Interstitial lung disease (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)